Roger Bullock

12.2k total citations · 3 hit papers
138 papers, 6.8k citations indexed

About

Roger Bullock is a scholar working on Psychiatry and Mental health, Pharmacology and Physiology. According to data from OpenAlex, Roger Bullock has authored 138 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Psychiatry and Mental health, 25 papers in Pharmacology and 21 papers in Physiology. Recurrent topics in Roger Bullock's work include Dementia and Cognitive Impairment Research (38 papers), Cholinesterase and Neurodegenerative Diseases (22 papers) and Child Welfare and Adoption (20 papers). Roger Bullock is often cited by papers focused on Dementia and Cognitive Impairment Research (38 papers), Cholinesterase and Neurodegenerative Diseases (22 papers) and Child Welfare and Adoption (20 papers). Roger Bullock collaborates with scholars based in United Kingdom, United States and Canada. Roger Bullock's co-authors include Bernadette McGuinness, Peter Passmore, David Craig, Sean Lilienfeld, Serge Gauthier, Timo Erkinjuntti, Clive Holmes, Roy Jones, Alexander Kurz and C. V. Damaraju and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Blood.

In The Last Decade

Roger Bullock

120 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

2008 1.1k citations Clive Holmes, Roger Bullock et al. The Lancet profile →
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

2010 536 citations Juha O. Rinne, David J. Brooks et al. The Lancet Neurology profile →
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

2002 523 citations Timo Erkinjuntti, Alexander Kurz et al. The Lancet profile →

Peers

Countries citing papers authored by Roger Bullock

Since Specialization

Citations

This map shows the geographic impact of Roger Bullock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Bullock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Bullock more than expected).

Fields of papers citing papers by Roger Bullock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Bullock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Bullock. The network helps show where Roger Bullock may publish in the future.

Co-authorship network of co-authors of Roger Bullock

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Bullock. A scholar is included among the top collaborators of Roger Bullock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Bullock. Roger Bullock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders 2025 ·Psychiatry and Clinical Neurosciences ·Marc Ferrer, Vanesa Richarte, Laura Gisbert, Jordi Xaus, (unknown), (unknown), Michael T. Ropacki, Roger Bullock, Carlos Buesa, Josep Antoni Ramos‐Quiroga	1
2	Potential Virus Involvement in Alzheimer’s Disease: Results from a Phase IIa Trial Evaluating Apovir, an Antiviral Drug Combination 2021 ·Journal of Alzheimer s Disease Reports ·Nina Lindblom, Lars Lindquist, Jacob Westman, Mikael Åström, Roger Bullock, Suzanne Hendrix, Lars‐Olof Wahlund	13
3	Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial 2012 ·The Lancet ·(unknown), V. P. Prasher, Nicola Williams, (unknown), Dag Aarsland, Anne Corbett, Dale N. Lawrence, Ly‐Mee Yu, Stephen Tyrer, Paul T. Francis, Tony Johnson, Roger Bullock, Clive Ballard	105
4	11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study breakdown → 2010 ·The Lancet Neurology ·Juha O. Rinne, David J. Brooks, Martin N. Rossor, Nick C. Fox, Roger Bullock, William E. Klunk, Chester A. Mathis, Kaj Blennow, Jerome Barakos, Aren Okello, (unknown), Enchi Liu, Martin Koller, Keith M. Gregg, Dale Schenk, Ronald S. Black, Michael Grundman	536
5	Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease 2010 ·CNS Neuroscience & Therapeutics ·Murat Emre, Roberto Bernabei, Rafael Blesa, Roger Bullock, Luı́s Cunha, (unknown), Edward K. Dziadulewicz, Hans Förstl, Lutz Frölich, Tomasz Gabryelewicz, О С Левин, James Lindesay, Pablo Martínez‐Lage, Andreas U. Monsch, Magda Tsolaki, Teus van Laar	27
6	Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial) 2009 ·American Journal of Geriatric Psychiatry ·Clive Ballard, Richard G. Brown, Jane Fossey, Simon Douglas, Paul Bradley, (unknown), Ian James, Edmund Juszczak, Peter Bentham, Alistair Burns, James Lindesay, Robin Jacoby, John T. O’Brien, Roger Bullock, Tony Johnson, Clive Holmes, Robert Howard	62
7	A breath of pragmatism 2007 ·Advances in Psychiatric Treatment ·Roger Bullock	1
8	P1–434: Apathy and depressive symptoms in Alzheimer's disease. Results from the European Alzheimer's Disease Consortium 2006 ·Alzheimer s & Dementia ·Philippe Robert, (unknown), Pauline Aalten, Flavio Nobili, (unknown), Roger Bullock, (unknown), Éric Salmon, Giovanni B. Frisoni, Clive Holmes, Patrizia Mecocci, (unknown)	1
9	Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants 2006 ·International Psychogeriatrics ·Lori Frank, Andrew R. Lloyd, Jennifer Flynn, Leah Kleinman, Louis S. Matza, Mary Kay Margolis, Lee Bowman, Roger Bullock	101
10	Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease 2006 ·Current Medical Research and Opinion ·Roger Bullock, Howard Bergman, Jacques Touchon, Giuseppe Gambina, Yunsheng He, (unknown), Roger Lane	47
11	Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings 2004 ·Current Medical Research and Opinion ·Roger Bullock	40
12	The Needs of the Caregiver in the Long-Term Treatment of Alzheimer Disease 2004 ·Alzheimer Disease & Associated Disorders ·Roger Bullock	46
13	Cholinesterase Inhibitors and Vascular Dementia 2004 ·CNS Drugs ·Roger Bullock	20
14	Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia 2004 ·Journal of the Neurological Sciences ·Gustavo C. Román, Perminder S. Sachdev, Donald R. Royall, Roger Bullock, Jean-Marc Orgogozo, Secundino López‐Pousa, Raúl L. Arizaga, Anders Wallin	207
15	Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine 2003 ·Dementia and Geriatric Cognitive Disorders ·Roger Bullock, Timo Erkinjuntti, Sean Lilienfeld, (unknown)	35
16	An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia 2003 ·Clinical Therapeutics ·Timo Erkinjuntti, Alexander Kurz, Gary W. Small, Roger Bullock, Sean Lilienfeld, C. V. Damaraju	59
17	Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial breakdown → 2002 ·The Lancet ·Timo Erkinjuntti, Alexander Kurz, Serge Gauthier, Roger Bullock, Sean Lilienfeld, C. V. Damaraju	523
18	Reboxetine in the treatment of depression: Early clinical experience in the UK 1998 ·International Journal of Psychiatry in Clinical Practice ·David S. Baldwin, (unknown), E. Szabadi, (unknown), J. Anderson Thomson, Roger Bullock, (unknown)	8
19	An enhanced classification approach to change detection in semi-arid environments 1988 ·Photogrammetric Engineering & Remote Sensing ·(unknown), Philip J. Howarth, Roger Bullock, (unknown)	129
20	Landscape change in Kiambu 1965 ·Roger Bullock	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact